Objective (range, 5-47 months) 
Introduction

Aminoacyl-tRNA synthetase (ARS) is a family of cytoplasmic enzymes that catalyze formation of aminoacyl-tRNA from a specific amino acid and its cognate tRNA and play a crucial role in protein synthesis. Eight anti-ARS autoantibodies have been identified until date. These include antihistidyl (anti-Jo-1), anti-threonyl (anti-PL-7), anti-alanyl (anti-PL-12), anti-isoleucyl (anti-OJ), anti-glycyl (anti-EJ), anti-asparaginyl (anti-KS), anti-phenylalanyl (anti-Zo), and anti-tyrosyl-tRNA synthetases (1-3). Anti-ARS autoantibodies are associated with myositis, arthritis, and interstitial lung disease (ILD), clinically referred to as "anti-synthetase syndrome" (2).
There
have been few reports that showed the clinical, radiographic, and pathological findings of ILD patients with anti-ARS autoantibodies. The aim of this study was to investigate the clinicopathological characteristics and the response to treatments in 14 ILD patients with anti-ARS autoantibodies. These results indicate that they generally have a chronic clinical course, lung-base predominant ground glass opacities (GGO) with volume loss, nonspecific interstitial pneumonia (NSIP) patterns, and a good response to corticosteroid treatment.
Patients and Methods
Patients
We evaluated 14 Katzenstein's classification (6) . Chest high-resolution computed tomography (HRCT) on
Response to treatment
Response to ILD treatment was determined according to the criteria of the response to idiopathic pulmonary fibrosis treatment in the international consensus statement of the ATS and ERS (7).
Results
Clinical, laboratory, and radiographic findings
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admission revealed GGO with peribronchovascular interstitial thickening and traction broncho-bronchioloectasis in 10 patients, and 5 also had consolidation ( (11, 12) , the same as our patient with PM and ILD. (15, 18, 19) , 10% had anti-La/SS-B antibodies (18, 19) , and 10% had anti-RNP antibodies (19) . Moreover, anti-Ro/S-AA antibodies were detected most frequently in PM/DM patients with anti-ARS autoantibodies (20) .
In 2 patients of our series, anti-Jo-1 antibodies changed to positive during follow-up after the onset of both ILD and myositis. In a patient who was considered to have IIP, it has been reported that anti-Jo-1 became with positive before the onset of myositis (13). It suggests that changing to positive for anti-ARS autoantibodies and the onset of ILD or myositis may vary in anti-synthetase syndrome. Even if anti-ARS antibodies are initially negative in patients with ILD or myositis, it is useful to reexamine the autoantibodies during follow-up. With regard to the onset time of myositis and ILD in antisynthetase syndrome, myositis-preceding type constitutes 7%-33%, ILD-preceding type is 29%-50%, and the simultaneous type is 38%-60% (12, 14, 15). Our patients with myositis and ILD had a similar composition. This finding suggests that the detection of anti-ARS autoantibodies in patients with either myositis or ILD is useful for predicting the coincidence of another condition. Here, 3 of 14 patients (21%) had a complication of a CVD other than PM/DM, such as MCTD, PM-RA-SSc overlap, and secondary SjS. It was reported that 18%-25% of patients with anti-ARS autoantibodies presented with overlap syndrome of PM/DM and other CVD (16, 17). They included RA, lupus, and SSc, as well as sicca syndrome in 59% of patients with anti-synthetase syndrome (18). In our study, 2 (14%) of the 14 patients had anti-Ro/S-AA antibodies. In patients with anti-ARS autoantibodies, 24%-25% had anti-Ro/S-AA antibodies
In our study, 1 patient had a medical history of a postoperative ovarian low malignant potential tumor, and 1 patient had squamous cell lung carcinoma as a complication. Patients with anti-synthetase syndrome do not often have malignancies (18, 19) ; however, they may present with cancerassociated myositis, and the coincidence of malignancies requires attention.
Most patients with anti-ARS autoantibodies have chronic and mild ILD, but some patients presenting with acute ILD suffer severe, rapidly progressive courses (21, 22) . None of our patients had severe ILD with less than 60 Torr of PaO2, and most patients had a chronic clinical course. However, (23, 24 (18) . ILD patients with anti-Jo-1 antibodies have predominant CD8 lymphocytosis in bronchoalveolar lavage fluids (26) . Similarly, we frequently found increased percentages of lymphocytes and decreased CD4/CD8 ratios in bronchoalveolar lavage fluid.
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F i g u r e 1 . Ch e s t h i g h -r e s o l u t i o n c o mp u t e d t o mo g r a p h y ( HRCT ) f i n d i n g s o f p a t i e n t 1 ( A, B ) a n d 1 1 ( C, D) . A: Ch e s t HRCT f i n d i n g s o f p a t i e n t 1 o n a d mi s s i o n s h o ws g r o u n d g l a s s o p a c i t i e s ( GGO) a n d c o n s o l i d a t i o n wi t h v o l u me l o s s t h a t p r e s e n t e d i n t h e l u n g b a s e a n d wa s p e r i b r o n c h o v a s c u l a r p r e d o mi n a n t . B : I n p a t i e n t 1 , GGO a n d v o l u me l o s s i mp r o v e d 2 mo n t h s a f t e r s t a r t i n g t h e r a p y . C: Ch e s t HRCT f i n d i n g s o f p a t i e n t 1 1 o n a d mi s s i o n s h o ws GGO a n d c o n s o l i d a t i o n s wi t h v o l u me l o s s p r e s e n t e d i n t h e l o we r l o b e a n d p e r i b r o n c h o v a s c u l a r p r e d o mi n a n t . D: I n p a t i e n t 1 1 , GGO a n d v o lu me l o s s i mp r o v e d 3 . 5 mo n t h s a f t e r s t a r t i n g t h e r a p y . some patients (29%) presented with subacute deterioration, thus suggesting that attention should be paid to acute deterioration during follow-up. Most ILD patients with anti-ARS autoantibodies present with either an abnormal chest radiograph without symptoms or slowly progressive dyspnea (22). In our 14 patients, 3 asymptomatic patients had abnormal shadows in the chest, thus indicating that there are many asymptomatic ILD patients with anti-ARS autoantibodies. Most of the present patients had elevated levels of KL-6, SP-A, and SP-D. A similar finding was also reported in previous studies
Chest HRCT of ILD patients with PM/DM revealed frequent reticular opacities, GGO, and consolidation; however, honeycombing is rarely found (27) . It was reported that in ILD patients with anti-Jo-1, the predominantly inferior location was frequent, whereas honeycombing was rare (26) . In our study, lung-base predominant GGO with or without con-
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o r mi n g a n i n c o mp l e t e l y mp h f o l l i c l e ( He ma t o x y l i n a n d E o s i n s t a i n i n g , × 2 0 0 ) . (Figs. 1A and 1C) (21) .
solidation was frequently identified
Here, 13 of the patients received therapy with corticoster-
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